Evidence map›Paper›PMID 40140663›Full record

ArticleNature communications2025

Structural insights into lipid chain-length selectivity and allosteric regulation of FFA2.

Mai Kugawa, Kouki Kawakami, Ryoji Kise, Carl-Mikael Suomivuori, Masaki Tsujimura, Kazuhiro Kobayashi, Asato Kojima, Wakana J Inoue, Masahiro Fukuda, Toshiki E Matsui and 10 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Optimized bacterial expression of a synthetic BRIL antibody.Acta crystallographica. Section F, Structural biology communications · 2026
    Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Mai Kugawa *Research Center for Advanced Science and Technology, The University of Tokyo, Meguro, Tokyo, Japan.
Kouki Kawakami *Research Center for Advanced Science and Technology, The University of Tokyo, Meguro, Tokyo, Japan.ORCID http://orcid.org/0000-0002-2507-8619
Ryoji Kise *Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.
Carl-Mikael SuomivuoriDepartment of Computer Science, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-2445-8791
Masaki TsujimuraDepartment of Advanced Interdisciplinary Studies, The University of Tokyo, Meguro, Tokyo, Japan.ORCID http://orcid.org/0000-0002-7554-7372
Kazuhiro KobayashiResearch Center for Advanced Science and Technology, The University of Tokyo, Meguro, Tokyo, Japan.ORCID http://orcid.org/0000-0002-3366-3586
Asato KojimaResearch Center for Advanced Science and Technology, The University of Tokyo, Meguro, Tokyo, Japan.
Wakana J InoueDepartment of Life Sciences, School of Arts and Sciences, The University of Tokyo, Meguro, Tokyo, Japan.
Masahiro FukudaResearch Center for Advanced Science and Technology, The University of Tokyo, Meguro, Tokyo, Japan.ORCID http://orcid.org/0000-0002-8824-846X
Toshiki E MatsuiResearch Center for Advanced Science and Technology, The University of Tokyo, Meguro, Tokyo, Japan.
Ayami FukunagaResearch Center for Advanced Science and Technology, The University of Tokyo, Meguro, Tokyo, Japan.
Junki KoyanagiDepartment of Life Sciences, School of Arts and Sciences, The University of Tokyo, Meguro, Tokyo, Japan.
Suhyang KimResearch Center for Advanced Science and Technology, The University of Tokyo, Meguro, Tokyo, Japan.
Hisako IkedaResearch Center for Advanced Science and Technology, The University of Tokyo, Meguro, Tokyo, Japan.
Keitaro YamashitaResearch Center for Advanced Science and Technology, The University of Tokyo, Meguro, Tokyo, Japan.ORCID http://orcid.org/0000-0002-5442-7582
Keisuke SaitoResearch Center for Advanced Science and Technology, The University of Tokyo, Meguro, Tokyo, Japan.ORCID http://orcid.org/0000-0002-2293-9743
Hiroshi IshikitaResearch Center for Advanced Science and Technology, The University of Tokyo, Meguro, Tokyo, Japan.ORCID http://orcid.org/0000-0002-5849-8150
Ron O DrorDepartment of Computer Science, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-6418-2793
Asuka InoueGraduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan. iaska@tohoku.ac.jp.ORCID http://orcid.org/0000-0003-0805-4049
Hideaki E KatoResearch Center for Advanced Science and Technology, The University of Tokyo, Meguro, Tokyo, Japan. c-hekato@g.ecc.u-tokyo.ac.jp.ORCID http://orcid.org/0000-0002-1941-5535

Funding

Japan Agency for Medical Research and Development (AMED) 24bm1123057h0001MEXT | Japan Science and Technology Agency (JST) JPMJFR204SMEXT | Japan Society for the Promotion of Science (JSPS) JP21H04791MEXT | Japan Society for the Promotion of Science (JSPS) JP21H05142MEXT | JST | Core Research for Evolutional Science and Technology (CREST) JPMJCR21P3MEXT | JST | Core Research for Evolutional Science and Technology (CREST) JPMJCR23B1
6 · The paper itself

Abstract

The free fatty acid receptor 2 (FFA2) is a G protein-coupled receptor (GPCR) that selectively recognizes short-chain fatty acids to regulate metabolic and immune functions. As a promising therapeutic target, FFA2 has been the focus of intensive development of synthetic ligands. However, the mechanisms by which endogenous and synthetic ligands modulate FFA2 activity remain unclear. Here, we present the structures of the human FFA2-Gi complex activated by the synthetic orthosteric agonist TUG-1375 and the positive allosteric modulator/allosteric agonist 4-CMTB, along with the structure of the inactive FFA2 bound to the antagonist GLPG0974. Structural comparisons with FFA1 and mutational studies reveal how FFA2 selects specific fatty acid chain lengths. Moreover, our structures reveal that GLPG0974 functions as an allosteric antagonist by binding adjacent to the orthosteric pocket to block agonist binding, whereas 4-CMTB binds the outer surface of transmembrane helices 6 and 7 to directly activate the receptor. Supported by computational and functional studies, these insights illuminate diverse mechanisms of ligand action, paving the way for precise GPCR-targeted drug design.

Indexed as

Receptors, Cell SurfaceReceptors, G-Protein-CoupledAllosteric RegulationFatty AcidsHEK293 CellsHumansLigandsProtein BindingFatty AcidsFFAR2 protein, humanLigandsReceptors, Cell SurfaceReceptors, G-Protein-Coupled

Identifiers

PMID40140663
PMCPMC11947310

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.